SLC5A2 and obstructive sleep apnea syndrome: When analyzing the effects of SGLT2-i on OSA incidence, Wojeck et al. reported a 48% relative risk reduction in the development of OSA in HF patients treated with ertugliflozin compared to placebo [42].